Damora Therapeutics, Inc. (DMRA) stock
DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
$22.56+0.06 (+0.29%)
Close on Nov 17, 2026Market cap $1.39BP/E 5.7Yield 0.00%
Damora Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Damora Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$59.13M. For fiscal 2025 it was -$6.73M. The highest annual figure on record is -$6.73M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.73M | – |
| FY2024 | Dec 31, 2024 | -$18.62M | – |
| FY2023 | Dec 31, 2023 | -$36.91M | – |
| FY2022 | Dec 31, 2022 | -$42.93M | – |
| FY2021 | Dec 31, 2021 | -$52.31M | – |
| FY2020 | Dec 31, 2020 | -$38.20M | – |
| FY2019 | Dec 31, 2019 | -$19.33M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$17.23M | – |
| Q2 FY2026 | Jun 30, 2026 | -$21.87M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.60M | – |
| Q4 FY2025 | Dec 31, 2025 | $566.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.62M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.24M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.44M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.94M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.65M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.10M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.94M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.47M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.45M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.85M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.13M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.45M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.85M | – |
| Q2 FY2022 | Jun 30, 2022 | -$14.84M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.80M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.83M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.16M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.17M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.15M | – |
| Q4 FY2020 | Dec 31, 2020 | -$14.52M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.58M | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.13M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.98M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.25M | – |
See a number that looks wrong?